本帖最后由 老马 于 2012-1-13 21:20 编辑
! c5 ^; B) R, B& q! _# Z
' {1 M% W# ]' g; m爱必妥和阿瓦斯丁的比较* z! X* X- k+ T
+ p' N7 W* Y8 n# l2 s
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
1 M% G6 i) ]0 }: {" I
* F; g! H' ?* G
/ q5 C9 Z' Y- Q4 e s7 R
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
9 [" @9 y( b$ c$ h; W1 }, \9 E==================================================+ Z+ a) v0 i0 F3 A3 N1 k
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
+ G9 f7 ] f0 F0 }Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
0 e, {, T: W. _9 i7 D/ h% Z, N( lResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.+ J( H: Q T+ C8 H: e E% ]) p" R m
|